Combining photodynamic therapy and feeder vessel photocoagulation: A pilot study

Giovanni Staurenghi, Amedeo Massacesi, Ilenia Musicco, Paola Salvetti, Francesco Viola

Research output: Contribution to journalArticlepeer-review


Patients receiving photodynamic therapy (PDT) with verteporfin (Visudyne®, Novartis AG), a new treatment for subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and pathologic myopia, should be scheduled for follow-up every 12 weeks (±2 weeks) after the initial treatment. However, important data from clinical practice and from small series studies suggest that this period between treatment may be too long for some patients. In this pilot study we explore the safety and the possibility of improving the extent and duration of PDT benefit using feeder vessel treatment (FVT). This study suggests that the combination of verteporfin therapy and FVT is a safe procedure; it also suggests a possibility for prolonging the effect of verteporfin therapy.

Original languageEnglish
Pages (from-to)233-236
Number of pages4
JournalSeminars in Ophthalmology
Issue number4
Publication statusPublished - Dec 2001


  • Age-related macular degeneration
  • Choroidal neovascularization
  • Feeder vessel treatment
  • Photodynamic therapy
  • Verteporfin

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Combining photodynamic therapy and feeder vessel photocoagulation: A pilot study'. Together they form a unique fingerprint.

Cite this